Skip to content

Author

M. Maffezzoli

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Cholesterol transporters and immune-metabolic features in patients with metastatic renal cell carcinoma receiving immunotherapy combinations.

BACKGROUND Despite improved outcomes with immune checkpoint inhibitor (ICI) combinations in metastatic renal cell carcinoma (mRCC), reliable biologically-driven prognostic markers remain needed. The CHOMET study evaluated tumor ABCA1/ABCG1 expression and their association with systemic lipid parameters, nutritional sta...

G. C. Giudice, Hassan M. Abushukair, G. Mazzaschi et al. · 0 citations
Review Open access Oct 2026

Non-Conventional Histologies of Prostate Cancer: From Morphology to Biology-Driven Precision Oncology.

Non-conventional prostate cancer histologies represent a small but clinically significant subset characterised by aggressive behaviour, atypical biomarker profiles, and reduced dependence on androgen receptor signalling. Evidence indicates these histologies reflect dynamic biological states driven by genomic instabilit...

F. Flauto, G. Neola, Alessia Cimadamore et al. · 0 citations
Review Open access Sep 2026

Global management of drug–drug interaction in patients with prostate cancer: international survey by Meet-URO group and ONCOassist

Abstract Background Patients with prostate cancer (PC) frequently receive multiple medications for comorbidities, increasing the risk of drug–drug interactions (DDIs). Despite guidelines highlighting DDI relevance, data on real-world management are limited. This international survey aimed to characterize current practi...

A. A. Valsecchi, M. Maffezzoli, M. Cursano et al. · 0 citations
Review Open access Aug 2026

Molecular biomarkers in metastatic clear cell renal cell carcinoma treated with first-line immune combinations: a systematic review of phase III randomized clinical trials by Meet-URO group

Immune checkpoint inhibitor (ICI)–based combinations represent the standard first-line treatment for metastatic clear cell renal cell carcinoma (mRCC), although robust biomarkers for treatment selection remain undefined. We conducted a systematic review to identify biomarkers assessed in randomized clinical trials (RCT...

A. A. Valsecchi, M. Maffezzoli, M. Cursano et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.